Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-681323 in coronary heart disease patients undergoing elective PCI
2005-004285-16Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing SB-681323 with Placebo (2 arms). Primary endpoint: Incidence of liver function abnormalities. Started Dec 2005; status: completed.
02
Drugs
dilmapimod
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2005-004285-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004285-16.